カテゴリ： GlobalData, アメリカ, 企業調査

Cytodyn Inc (CYDY)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Cytodyn Inc (CYDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7984
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：73
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company’s products pipeline include PRO 140, Cytofeline and Cytolin. Cytodyn’s PRO 140 is a viral-entry inhibitor intended to protect healthy cells from viral infection which blocks the HIV co-receptor C-C chemokine receptor type 5 (CCR5) on T-cells. Cytofeline, a anti-LFA-1 antibody is used for the treatment of FIV infection. Cytolin is a mouse monoclonal antibody developed to identify a immune cell called cytotoxic T cell (CTL). Cytodyn is headquartered in Vancouver, Washington, the US.

Cytodyn Inc (CYDY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cytodyn Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12
Venture Financing 14
ProstaGene Raises USD0.4 Million in Financing 14
Cytodyn Raises USD2.7 million in Financing Round 15
CytoDyn Raises USD3.3 million in Venture Financing Round 16
ProstaGene Raises USD0.4 Million in Venture Financing 17
Partnerships 18
CytoDyn Amends Research Agreement with Drexel University College of Medicine 18
Licensing Agreements 19
CytoDyn Enters into Licensing Agreement with Lonza Sales 19
Equity Offering 20
CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20
CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22
CytoDyn Raises USD1.2 Million in Private Placement of Shares 23
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24
CytoDyn Raises USD4.3 Million in Private Placement of Shares 25
CytoDyn Raises USD7.3 Million in Private Placement of Shares 26
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 27
CytoDyn Raises USD14.5 Million in Private Placement of Units 28
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 29
Debt Offering 30
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 33
Acquisition 34
CytoDyn to Acquires ProstaGene 34
Cytodyn Inc – Key Competitors 35
Cytodyn Inc – Key Employees 36
Cytodyn Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Corporate Communications 38
Jan 30, 2017: CytoDyn appoints executive chairman 38
Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 39
Product News 40
12/07/2017: Independent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint 40
08/21/2017: CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 41
08/09/2017: CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial 42
07/12/2018: CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders 43
07/12/2018: CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders 45
06/11/2018: CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA 47
06/09/2018: Weekly Injections of CytoDyns PRO 140 in Combination with Optimized Antiretroviral Treatment Shows Long-Acting HIV-1 Viral Suppression 48
06/04/2018: Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9 49
06/01/2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 50
04/11/2018: CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 51
04/11/2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 52
03/29/2018: CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders 53
02/20/2018: CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection 54
01/30/2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 56
Product Approvals 57
Jun 22, 2018: CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy 57
Mar 14, 2018: CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD 58
Oct 13, 2017: CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA 59
Oct 05, 2017: CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease 60
Sep 06, 2017: CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 61
Apr 17, 2017: Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 62
Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 63
Clinical Trials 64
Jul 30, 2018: Cytodyn announces significantly improved response rate at higher dose of PRO 140 in HIV phase 3 monotherapy trial 64
Jul 16, 2018: CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial 66
Jun 26, 2018: New Research Supports Potential for CytoDyn’s PRO 140 to Inhibit Breast Cancer Metastasis 67
Jun 20, 2018: CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD 68
May 24, 2018: Results of CytoDyns PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials 69
Nov 14, 2017: CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation 70
May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 71
Feb 14, 2017: Two-Year Update From CytoDyn’s PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Cytodyn Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12
ProstaGene Raises USD0.4 Million in Financing 14
Cytodyn Raises USD2.7 million in Financing Round 15
CytoDyn Raises USD3.3 million in Venture Financing Round 16
ProstaGene Raises USD0.4 Million in Venture Financing 17
CytoDyn Amends Research Agreement with Drexel University College of Medicine 18
CytoDyn Enters into Licensing Agreement with Lonza Sales 19
CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20
CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22
CytoDyn Raises USD1.2 Million in Private Placement of Shares 23
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24
CytoDyn Raises USD4.3 Million in Private Placement of Shares 25
CytoDyn Raises USD7.3 Million in Private Placement of Shares 26
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 27
CytoDyn Raises USD14.5 Million in Private Placement of Units 28
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 29
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 33
CytoDyn to Acquires ProstaGene 34
Cytodyn Inc, Key Competitors 35
Cytodyn Inc, Key Employees 36
Cytodyn Inc, Subsidiaries 37

List of Figures
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Cytodyn Inc (CYDY)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Journey Energy Inc (JOY)：企業の財務・戦略的SWOT分析
    Summary Journey Energy Inc (Journey Energy), a subsidiary of Maples Investments LP, is an oil and gas company that offers exploration, development and production oil and natural gas assets. The company provides horizontal and multi-frac drilling, and secondary recovery methods that helps in acquirin …
  • EBOS Group Ltd (EBO)：製薬・医療：M&Aディール及び事業提携情報
    Summary EBOS Group Ltd (EBOS) is a healthcare products supplier that markets, sells and distributes healthcare, medical and pharmaceutical products. It also markets and distributes animal care products and offers distribution, warehousing and logistics support to pharmaceutical manufacturers and med …
  • Cognizant Technology Solutions Corporation：戦略・SWOT・企業財務分析
    Cognizant Technology Solutions Corporation - Strategy, SWOT and Corporate Finance Report Summary Cognizant Technology Solutions Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Rutgers The State University of New Jersey-医療機器分野：企業M&A・提携分析
    Summary Rutgers The State University of New Jersey (Rutgers) is a research university that offers undergraduate and postgraduate programs, and research in the areas of health sciences. The university provides continuing education for professional and personal advancement. It offers courses in the ar …
  • YRC Worldwide Inc (YRCW)：企業の財務・戦略的SWOT分析
    YRC Worldwide Inc (YRCW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Merit Medical Systems Inc (MMSI)：企業の財務・戦略的SWOT分析
    Merit Medical Systems Inc (MMSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Kansas Electric Power Cooperative, Inc.：企業の戦略的SWOT分析
    Kansas Electric Power Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • IMCD N.V.：企業のM&A・事業提携・投資動向
    IMCD N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IMCD N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Crown Point Energy Inc (CWV)：企業の財務・戦略的SWOT分析
    Summary Crown Point Energy Inc (Crown Point), formerly Crown Point Ventures is an oil and gas company that offers oil and gas development and exploration services. The company acquires and produces crude oil and natural gas deposits. It holds interests in Cerro de Los Leones exploration concessions …
  • China Datang Corp：電力：M&Aディール及び事業提携情報
    Summary China Datang Corp (CDT) is engaged in development, investment, construction, operation and management of power generation assets. The company provides electric power equipment, environment protection device, memory card and card reader; religion crafts, meter for electricity, safety products …
  • Blue Label Telecoms Ltd (BLU)：企業の財務・戦略的SWOT分析
    Blue Label Telecoms Ltd (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Adani Enterprises Ltd (ADANIENT)：石油・ガス：M&Aディール及び事業提携情報
    Summary Adani Enterprises Ltd (Adani) is a diversified company with operations in resources, logistics and energy. It has interests in various businesses such as coal trading and mining, bunkering, renewable power generation, defense and aerospace, ports and special economic zones (SEZ), logistics, …
  • Prime Capital AG-エネルギー分野：企業M&A・提携分析
    Summary Prime Capital AG (Prime Capital) is a financial service provider that offers asset management and professional services. The company provides infrastructure investments including renewable energy, private debt and hedge fund strategies through its independent asset management and advisory se …
  • Dr. August Oetker Kg：企業の戦略・SWOT・財務分析
    Dr. August Oetker Kg - Strategy, SWOT and Corporate Finance Report Summary Dr. August Oetker Kg - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Windflow Technology Ltd (WTL)：企業の財務・戦略的SWOT分析
    Windflow Technology Ltd (WTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cardiatis SA：製品パイプライン分析
    Summary Cardiatis SA (Cardiatis) is a medical device company that develops a multilayer technology platform for endovascular aneurysm. The company offers a three dimensional multilayer braided stent system for endovascular aneurysm repair. Its multilayer flow modulator include aortic, peripheral, bi …
  • Owensboro Municipal Utilities：企業の戦略的SWOT分析
    Owensboro Municipal Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • AutoZone, Inc.：戦略・SWOT・企業財務分析
    AutoZone, Inc. - Strategy, SWOT and Corporate Finance Report Summary AutoZone, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • JM Financial Private Wealth Group：企業の戦略・SWOT・財務情報
    JM Financial Private Wealth Group - Strategy, SWOT and Corporate Finance Report Summary JM Financial Private Wealth Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Disco Corp (6146)：企業の財務・戦略的SWOT分析
    Disco Corp (6146) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆